

Title Page

**Manuscript Title: Efficacy of Anakinra in the Management of Patients with
COVID-19 Infection: A Randomized Clinical Trial**

Running Title: Anakinra in COVID-19 Infection

Authors Affiliations

Eman Zeyad I. Elmekaty*, PharmD

Communicable Diseases Center, Hamad Medical Corporation

PO BOX 3050, Doha, Qatar

Email: eelmekaty@hamad.qa

Aya Maklad, PharmD

College of Pharmacy, QU Health, Qatar University,

PO BOX 2713, Doha, Qatar

Email: am1402005@student.qu.edu.qa

Rawan Abouelhassan, PharmD

College of Pharmacy, QU Health, Qatar University,

PO BOX 2713, Doha, Qatar

Email: ra1406526@student.qu.edu.qa

Waqar Munir, CABM

Communicable Diseases Center, Hamad Medical Corporation

PO BOX 3050, Doha, Qatar

Email: WMunir@hamad.qa

Mohamed Izham Mohamed Ibrahim, PhD

Clinical Pharmacy & Practice Department, College of Pharmacy, QU Health, Qatar
University

PO Box: 2713, Doha, Qatar.

Email: mohamedizham@qu.edu.qa

28 **Arun Nair, MBBS MD**

29 Communicable Diseases Center, Hamad Medical Corporation

30 PO BOX 3050, Doha, Qatar

31 Email: ANair9@hamad.qa

32 **Rim Alibrahim, PharmD**

33 Communicable Diseases Center, Hamad Medical Corporation

34 PO BOX 3050, Doha, Qatar

35 Email: RALibrahim@hamad.qa

36 **Fatima Iqbal, PharmD**

37 Communicable Diseases Center, Hamad Medical Corporation

38 PO BOX 3050, Doha, Qatar

39 Email: FIqbal1@hamad.qa

40 **Ahmad Al Bishawi, MD**

41 Communicable Diseases Center, Hamad Medical Corporation

42 PO BOX 3050, Doha, Qatar

43 Email: AAlBishawi@hamad.qa

44 **Alaaeldin Abdelmajid, MD**

45 Communicable Diseases Center, Hamad Medical Corporation

46 PO BOX 3050, Doha, Qatar

47 Email: AAbdelmajid@hamad.qa

48 **Mohamed Aboukamar, CABM**

49 Communicable Diseases Center, Hamad Medical Corporation

50 PO BOX 3050, Doha, Qatar

51 Email: Mkamar@hamad.qa

52 **Mohammed Abu Khattab, CABM**

53 Communicable Diseases Center, Hamad Medical Corporation

54 PO BOX 3050, Doha, Qatar

55 Email: MABUKHATTAB@hamad.qa

56 **Hussam Al Soub**, CABM

57 Communicable Diseases Center, Hamad Medical Corporation

58 PO BOX 3050, Doha, Qatar

59 Email: HALSOUB@hamad.qa

60 **Muna Al Maslamani**, MBBS MSc-HCM

61 Medical Director of Communicable Diseases Center, Hamad Medical Corporation

62 PO BOX 3050, Doha, Qatar

63 Email: MALMASLAMANI@hamad.qa

64

65

66

67

68 *** Corresponding Author**

69 Dr. Eman Zeyad Ibrahim Elmekaty, BSc (Pharm), PharmD, RPh, SIDP/ASCP, BCIDP

70 Clinical Pharmacist - Infectious Disease

71 Communicable Disease Center – HMC

72 Tel: (+974) 40254259

73 P.O. Box 3050 Doha, Qatar

74 Eelmekaty@hamad.qa

75

76

77

78 **Efficacy of Anakinra in the Management of Patients with COVID-19 Infection: A**
79 **Randomized Clinical Trial**

80 **Abstract**

81 **Background:** The global pandemic of COVID-19 infections continues to grow worldwide, with rising
82 number of deaths day by day. The hyperinflammation state contributes to the multiorgan failure
83 associated with COVID-19 infections. This study aims to explore the efficacy and safety of anakinra in
84 COVID-19 patients with both respiratory distress and cytokine release syndromes.

85
86 **Methods:** This was an open-label, multicenter, randomized clinical trial. Patients were randomized in 1:1
87 ratio to receive standard of care (SOC) alone, or anakinra plus SOC. Adults with confirmed COVID-19
88 infection with evidence of both respiratory distress and cytokine release syndrome were included. The
89 primary outcome was treatment success at day 14, defined as WHO clinical progression score of ≤ 3 . The
90 primary analysis was based on intention-to-treat population, with p-value of < 0.05 .

91
92 **Results:** A total of 80 patients were enrolled in the study. The mean age was 49.9 years (SD=11.7), with
93 82.5% (n=66) male patients. The primary outcome was not statistically different (87.5% (n=35) in
94 anakinra group vs. 92.5% (n=37) in SOC group, p=0.712). The majority of reported adverse events were
95 mild in severity and not related to the study treatment. Increased aspartate aminotransferase was the
96 only significant adverse event (35% (n=14) in anakinra group vs. 15% (n=6) in SOC group, p=0.039); yet,
97 was not associated with treatment discontinuation.

98
99 **Conclusion:** In patients with severe COVID-19 infection, the addition of anakinra to SOC treatment was
100 not associated with significant improvement in the WHO clinical progression scale. Further studies
101 investigating patients' subgroups that might benefit from anakinra are warranted. The trial was registered
102 at ClinicalTrials.gov (NCT04643678).

103

104 **Keywords:**

105 Anakinra, COVID-19, Interlukin-1 inhibitor, SARS-COV-2, Cytokine release syndrome, Severe pneumonia.

106 **Introduction:**

107 Since its declaration by the World Health Organization (WHO) in March 2020 as a global pandemic, the
108 severe acute respiratory syndrome coronavirus (SARS-CoV-2), also known as COVID-19, continues to
109 spread worldwide with increasing daily fatalities ^[1]. Subsequently, as of September 2021, the total number
110 of confirmed COVID-19 infections has exceeded 200,000,000 cases, with a total of 4,500,000 recorded
111 deaths globally ^[2]. Although the majority of confirmed infections present with mild to moderate clinical
112 presentations ranging from the absence of symptoms to the loss of taste or smell, headache, fatigue or
113 fever, COVID-19 may still result in consequent severe sequelae, including acute respiratory distress
114 syndrome (ARDS) and organ dysfunction syndrome along with an estimated mortality rate of 3.4% ^[3,4].

115 The infection acts as an essential source for activating macrophages, resulting in the release of pro-
116 inflammatory cytokines and chemokine macrophages primarily in the lungs, followed by subsequent
117 systemic release. This process is thought to play a major role in the pathophysiology of organ dysfunction
118 syndrome ^[5]. Furthermore, cytokine storm syndrome, a state of hyper-inflammation that contributes to
119 multiorgan failure, has proven to share considerable biochemical overlap with the hyper-inflammation
120 observed in patients with confirmed COVID-19 infections. Accordingly, recent evidence hypothesized that
121 screening COVID-19 patients for hyper-inflammation and consequently providing management with
122 immunosuppressive medications could improve mortality ^[6,7].

123 Anakinra, a recombinant non-glycosylated form of the human interleukin (IL)-1 receptor antagonist, has
124 demonstrated significant survival benefits in patients with macrophage activation syndrome (MAS) as
125 compared to placebo, with a 28-day mortality rate of 35% and 65%, respectively ($p = 0.0006$) in a subgroup
126 analysis of patients with hyper-inflammation as a result of severe sepsis ^[8]. Furthermore, numerous
127 studies revealed that the administration of anakinra was associated with an acceptable safety profile
128 where recent literature reported mild elevations in liver aminotransferases as the most common adverse
129 effect; however, such elevations were not clinically significant ^[9,10].

130 Meanwhile, ongoing trials are being conducted to investigate further the efficacy and safety profile of
131 anakinra in COVID-19 patients exhibiting features of cytokine storm during their illness. Thus far, a variety
132 of published data has shown promising results. However, such findings require extensive assessments in
133 a well-conducted randomized controlled trial to confirm the reported outcomes ^[11,12]. Currently, there are
134 no approved treatments directly targeted towards ceasing the cytokine storm and its consequences. Thus,
135 this randomized clinical, open-label trial aims to explore the efficacy and safety of anakinra in addition to

136 standard of care (SOC) compared to SOC alone in patients with confirmed COVID-19 infection with
137 respiratory distress and evidence of cytokine release syndrome.

138

139 **Methods:**

140 ***Study design and setting***

141 This study was a prospective randomized clinical, open-labeled, parallel assignments, multicenter trial.
142 Patients were recruited from three clinical sites in Qatar: Communicable Disease Center (CDC), Hazm
143 Mebaireek General Hospital (HMGH), and The Cuban Hospital (TCH) between 30 October 2020 till 30 April
144 2021. Eligible patients were randomized to receive either anakinra + SOC or SOC alone. The trial protocol
145 and the statistical analysis plan is available online. The trial was approved by the Institutional Review
146 Board at Hamad Medical Corporation (HMC) Medical Research Center (MRC-01-20-1095) and was
147 registered at ClinicalTrials.gov (NCT04643678).

148 ***Participants***

149 Hospitalized adults (age \geq 18yrs) were eligible for inclusion in the trial if they met the following eligibility
150 criteria: confirmed COVID-19 diagnosis by positive SARS-CoV2 Polymerase Chain Reaction (PCR) test and
151 associated presence of respiratory distress [defined as: $\text{PaO}_2/\text{FiO}_2 \leq 300$ mm Hg or respiratory Rate (RR)
152 ≥ 24 breaths/min or $\text{SpO}_2 \leq 94\%$ at room air], signs of cytokine release syndrome [defined as any of the
153 following at baseline: Ferritin > 600 mcg/L at presentation or > 300 mcg/l with doubling within 24 hours,
154 LDH > 250 IU/L, D-dimers > 1 mg/L, CRP > 70 mg/L and rising since last 24h with the absence of bacterial
155 infection, Interleukin-6 level > 10 x UNL (reference range ≤ 7 pg/ml)], radiological evidence of pneumonia
156 based on chest X-ray and/or computed tomography (CT) scan findings, and a signed informed consent
157 provided by the patient, or by the patient's legal representative. The exclusion criteria included known
158 serious allergic reactions including anaphylaxis to the study medication or any component of the product,
159 active infectious diseases such as active bacterial infections (defined as the isolation of bacteria from a
160 sterile body site or other body sites and is causing clinical symptoms and signs and therefore are treated
161 with antibiotics), invasive fungal infections, Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV)
162 infection, Hepatitis C Virus (HCV) infection, active tuberculosis, patients on immunosuppressants or
163 immunomodulatory drugs or had received any in the past 30 days, neutrophil count below 500
164 cells/microliter, platelets below 50,000/microliter, pregnant or breastfeeding females. A full list of
165 eligibility criteria is provided in the supplementary materials.

166 ***Randomization and masking***

167 All admissions with a laboratory-confirmed SARS-CoV-2 infection and on respiratory distress were
168 screened for eligibility by the research team. Eligible patients were randomly assigned using simple
169 randomization at an allocation ratio of 1:1 to receive either anakinra plus SOC therapy or SOC therapy
170 alone. A random sequence of numbers was generated by an independent biostatistician using a
171 computerized system. Only the principle investigator was responsible to allocate the participant serial
172 number and inform the research team of the treatment allocation. Each participant was assigned an
173 identification code corresponding to a study treatment group. The study was not blinded due to practical
174 reasons and the differences in the dosage regimens and administrations between the study groups.

175 ***Interventions and Procedures***

176 Patients in the intervention group received anakinra (KINERET®, 100mg/0.67 ml in pre-filled syringe) 100
177 mg subcutaneous (SC) injection every 12 hours for 3 days, then 100 mg SC once daily from day 4 to day 7.
178 The total duration of anakinra was 7 days with a total of 10 doses. Patients with severe renal impairment
179 (creatinine clearance <30 ml/min) had a 50% decrease in dose (dose administered every other day).
180 Patients in the intervention group received anakinra in addition to standard of care therapy except for
181 tocilizumab, due to the contraindication of administering both agents concomitantly. Patients in the
182 comparator group received SOC therapy as per the local treatment guideline as approved by the Ministry
183 of Public Health (MoPH) in Qatar at that time (see supplementary material). According to the treating
184 physician's judgment, therapy was discontinued, or doses were adjusted based on the safety concerns or
185 issues related to concomitant drug interactions. Apart from the study interventions and related laboratory
186 and diagnostic assessments, patients were treated as part of standard care, with no co-medications,
187 medical procedures, or diet restrictions. The study had pragmatic and adaptive nature, which mimics the
188 usual clinical practice in a real-world setting and allows for changes in the management of COVID-19
189 patients and SOC therapy, as approved by the MoPH in the country.

190 After enrollment, a detailed review of the participant's medical profile was conducted by the research
191 team. Demographic, clinical, radiological, laboratory data were collected from each patient's profile. The
192 WHO Clinical Progression Scale^[13] was used to assess the patient's clinical condition on a daily basis and
193 was documented in the electronic data collection sheet. The worst score on each particular day was
194 selected and recorded. The data collection sheet was validated independently by two investigators. The
195 list of study procedures, timings, and follow-up is available in the supplementary materials.

196 All adverse events (AEs) that occurred during the hospital stay and up to 28 days from randomization were
197 reported. Participants were contacted by telephone using standardized telephone script on days 14 and
198 28 to ascertain information related to AEs. All AE were assessed for severity and graded using the Common
199 Terminology Criteria for Adverse Events (CTCAE) version 5⁽¹⁴⁾. A blinded assessor evaluated and validated
200 the AE's severity, seriousness, relatedness, and attribution using appropriate scales and/or definitions as
201 per the HMC IRB Standard Operating Procedure (SOP) guidelines.

202 ***Outcomes***

203 The primary outcome was treatment success on day 14, defined as a WHO Clinical Progression score of
204 ≤ 3 [Ambulatory mild disease: symptomatic, assistance needed]. Secondary outcomes included the
205 duration of mechanical ventilation in ventilated patients up to 14 days, changes in the WHO Clinical
206 Progression Score between day 1 and day 7, viral burden as measured by the change in SARS-CoV-2 PCR
207 Cycle Threshold (CT) at day 7 and day 10-14, time to ICU admission up to 28 days, the incidence of adverse
208 events up to 28 days, length of hospital stay up to 28 days, and all-cause mortality rate at hospital
209 discharge or at 28 days, whichever occurred first.

210 ***Statistical analysis:***

211 No published randomized trials evaluated the difference between the two study interventions at the time
212 of study planning to appropriately estimate the mean difference and compute the sample size calculation.
213 Therefore, a sample size of 80 patients was estimated for this RCT with parallel group design based on the
214 hypothesized effect size from published observational studies with 80% power to detect a difference in
215 the primary endpoint of 30%, with a two-sided type I error rate of 0.05 (alpha). Categorical data were
216 expressed by frequency (percentage), while continuous values were expressed as mean \pm SD or median
217 and interquartile range (IQR), as appropriate. Data were tested for their normality. Kolmogorov-Smirnov
218 test was carried to test for data normality. Continuous data were examined with the Mann-Whitney U or
219 independent t-test and categorical data with the chi-square and Fisher's Exact tests. Two-way repeated
220 measure ANOVA analyzed the changes of data over time in the two treatment groups. Factors significant
221 at univariate analysis ($p < 0.10$) were further assessed by the multivariable binary regression analysis. All
222 statistical analyses were carried out using the statistical package SPSS, version 27 (IBM Corp. Released
223 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp). The primary analysis was
224 based on an intention-to-treat population, including all participants randomized.

225

226 ***Role of the funding source***

227 The study is funded by Medical Research Center at Hamad Medical Corporation, Qatar. The study's funder
228 had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
229 The corresponding author has full access to the data and the final responsibility to submit for publication.

230 ***Ethics Statement***

231 The trial was approved by the Institutional Review Board at Hamad Medical Corporation (HMC) Medical
232 Research Center (MRC-01-20-1095) and was registered at ClinicalTrials.gov (NCT04643678). The trial was
233 conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of
234 Helsinki. An independent institutional review board and ethics committee approved the trial protocol and
235 any subsequent amendments. The safety of the participants and the evaluation of the benefit–risk balance
236 was overseen by an independent data safety monitoring committee. Written informed consent was
237 obtained from all participants or legally authorized representatives before initiating any trial-related
238 procedures. No additional administrative permissions were required to access the raw data. All data used
239 in this study were fully anonymized before their use.

240

241 **Results:**

242 ***Participants***

243 Between 30 October 2020 and 28 February 2021, 327 patients were screened for eligibility and 80 patients
244 were enrolled and randomized to the two study groups: 40 patients in anakinra group and 40 patients in
245 the SOC group. One patient in the SOC group was lost to follow-up and discharged from the hospital for
246 social reasons [Figure 1]. All patients randomized were included in the intention to treat analysis. As
247 enrolled patients were hospitalized during the treatment course, the compliance with study medication
248 was 100%.

249

250

251

252

253

254
255
256
257
258
259
260
261
262
263




Figure 1: Flow diagram

264
265 The baseline characteristics of the patients were summarized in table 1. No significant differences were
266 found ($p>0.05$) between the two treatment groups. The complete list of participants demographics,
267 clinical data, and concomitant medications is available in the supplementary materials.

Table 1: Baseline characteristics of the study population

Characteristic	Overall (n=80)	Anakinra (n=40)	Standard of care (n=40)	P-value
Mean Age, year (SD)	49.9 (11.7)	49.5 (12.2)	50.3 (11.4)	0.77
Gender, n (%)				0.556
Male	66 (82.5)	32 (80)	34 (85)	
Female	14 (17.5)	8 (20)	6 (15)	
WHO Nationality Region, n (%)				0.074
AFRO	1 (1.3)	1 (2.5)	0 (0)	
PAHO	1 (1.3)	0 (0)	1 (2.5)	
SEARO	34 (42.5)	13 (32.5)	21 (52.5)	
EURO	2 (2.5)	0 (0)	2 (5.0)	
EMRO	26 (32.5)	14 (35.0)	12 (30.0)	
WPRO	16 (20.0)	12 (30.0)	4 (10.0)	
Body Mass Index, median (IQR)	29.9 (27.3 - 32.9)	30.9 (7.0)	29.3 (5.2)	0.285
Smoking Status, n (%)				1.00

Non-Smoker	72 (90.0)	36 (90.0)	36 (90.0)	
Current Smoker	0 (0)	0	0	
Ex-Smoker	8 (10.0)	4 (10.0)	4 (10.0)	
Hospital, n (%)				0.535
CDC	18 (22.5)	11 (27.5)	7 (17.5)	
HMGH	44 (55.0)	20 (50.0)	24 (60.0)	
TCH	18 (22.5)	9 (22.5)	9 (22.5)	
Nurse Unit, n (%)				1.00
General Ward	70 (87.5)	35 (87.5)	35 (87.5)	
Intensive Care Unit	10 (12.5)	5 (12.5)	5 (12.5)	
Has at least one comorbidity, n (%)	37 (46.3)	17 (42.5)	20 (50.0)	0.501
Myocardial Infarction	7 (8.8)	2 (5.0)	5 (12.5)	0.432
Chronic Obstructive Pulmonary Disease	1 (1.3)	0 (0)	1 (2.5)	1
Liver Disease	1 (1.3)	1 (2.5)	0 (0)	1
Diabetes Mellitus	35 (43.8)	17 (42.5)	18 (45.0)	0.822
Kidney Disease	1 (1.3)	0 (0)	1 (2.5)	1
Charlson Comorbidity Index (CCI), n (%)				
<2	72 (90.0)	37 (92.5)	35 (87.5)	0.712
≥2	8 (10.0)	3 (7.5)	5 (12.5)	
Symptoms at baseline, n (%)				
Cough	75 (93.8)	36 (90.0)	39 (97.5)	0.359
Fever	69 (86.3)	34 (85.0)	35 (87.5)	0.745
Shortness of Breath	59 (73.8)	29 (72.5)	30 (75.0)	0.799
Sore Throat	12 (15.0)	4 (10.0)	8 (20.0)	0.21
Loss of Taste/Smell	5 (6.3)	2 (5.0)	3 (7.5)	1
Muscle/Joint pain	31 (38.8)	15 (37.5)	16 (40.0)	0.818
Chest Pain	15 (18.8)	8 (20.0)	7 (17.5)	0.775
Headache	13 (16.3)	8 (20.0)	5 (12.5)	0.363
Weakness	14 (17.5)	5 (12.5)	9 (22.5)	0.239
Gastrointestinal Side Effect	25 (31.3)	9 (22.5)	16 (40.0)	0.091
Vital signs at baseline, mean (SD)				
Temperature (Min)	36.4 (0.2)	36.32 (0.23)	36.3 (0.41)	0.148
Temperature (Max)	37.2 (0.6)	37.1 (0.7)	37.2 (0.6)	0.971
Systolic Blood Pressure (Min)	111.1 (13.0)	119.2 (19.2)	107.3 (16.9)	0.585
Systolic Blood Pressure (Max)	133.9 (15.5)	162.0 (29.6)	140.2 (15.4)	0.416
Diastolic Blood Pressure (Min)	63.5 (8.9)	73.2 (13.4)	56.5 (7.3)	0.7
Diastolic Blood Pressure (Max)	82.3 (10.4)	101.8 (16.2)	84.7 (9.5)	0.717
Heart Rate (Min)	67.2 (10.4)	62.6 (7.4)	67.5 (15.3)	0.601

Heart Rate (Max)	88.4 (13.4)	95.4 (12.3)	99.5 (33.9)	0.185
Respiratory Rate (Min)	18.1 (2.3)	14.2 (5.4)	18.5 (1.6)	0.702
Respiratory Rate (Max)	22.9 (4.4)	29.2 (5.5)	32.0 (4.9)	0.781
O ₂ Saturation % (Min)	93.4 (2.4)	93.0 (3.1)	92.3 (2.7)	0.782
WHO Score at baseline, median (IQR)	5 (0)	5.0 (0)	5.0 (0)	0.859
5 (%)	69 (86.3)	35 (87.5)	34 (85.0)	NA
6 (%)	8 (10.0)	2 (5.0)	6 (15.0)	NA
7 (%)	3 (3.7)	3 (7.5)	0	NA
Bilateral abnormality at baseline x-ray	74 (92.5)	38 (95.0)	36 (90.0)	0.675
Concomitant Medications				
Remdesivir (n, %)	67 (83.8)	36 (90.0)	31 (77.5)	0.13
Favipiravir (n, %)	42 (52.5)	18 (45.0)	24 (60.0)	0.179
Corticosteroids (n, %)	80 (100)	40 (100)	40 (100)	NA
Convalescent plasma (n, %)	54 (67.5)	24 (60.0)	30 (75.0)	0.152
Azithromycin (n, %)	63 (78.8)	33 (82.5)	30 (75.0)	0.412
Ceftriaxone (n, %)	63 (78.8)	29 (72.5)	34 (85.0)	0.172
Anticoagulant use (n, %)	79 (98.8)	39 (97.5)	40 (100)	1

268

269 The change in vital signs and laboratory data over time (i.e. from baseline to day 14) were illustrated in
 270 figures 1-36 in the supplementary materials. No significant difference over time in the two treatment
 271 groups was noted except for the lymphocyte count (marginal; $p=0.046$). Figure.2 demonstrates a
 272 significant change in WHO score ($p=0.000$) over 14 days.

273

274

275


276

277

278

279

280



281 Figure.2: Change in the WHO Clinical progression Score between days 1 and day 14

282 **Outcomes:**

283 Table 2 below illustrates the results of the primary and secondary outcomes for the two treatment groups.
 284 The percentage of patients with treatment success at day 14 was not significantly different between the
 285 two groups ($p=0.712$). None of the secondary outcomes were found to be statistically significant.

286

Table 2: Results of the primary and secondary outcomes

Outcome	Overall (n=80)	Anakinra (n=40)	Standard of care (n=40)	P-value
Primary outcome:				
Percentage of patients with treatment success at day 14, n (%)	72 (90.0)	35 (87.5)	37 (92.5)	0.712
Secondary outcomes:				
Duration of mechanical ventilation in ventilated patients up to day 14, median days (IQR)	6.50 (2.0)	6.50 (2.0)	NA	NA
Change in WHO score from baseline to day 7, median (IQR)	1 (0 - 1)	1 (1)	1 (1)	0.211
Change in viral burden (CT value) from baseline to day 7, median (IQR)	13.1 (7.8 - 23.2)	6.1 (14.9)	9.8 (7.7)	0.09
Change in viral burden (CT value) from baseline to day 10-14, median (IQR)	17.6 (8.5 - 23.9)	15.8 (16.0)	17.6 (17.0)	0.923
Time to ICU admission in non-ICU patients up to 28 days, median time (IQR)	6.0 (4.0 – 15.0)	7.5 (13.0)	6.0 (15.3)	1.00
Length of hospital Stay, median days (IQR)	10.0 (8.0 - 13.0)	10.0 (4)	10.0 (4)	0.064
All-cause mortality, n (%)	1 (1.25)	0 (0)	1 (2.5)	1.000

287

288 The association between baseline characteristics and the primary outcome was not statistically significant
 289 between the two groups (refer to supplementary materials).

290

291 **Safety Outcomes**

292 Two DSMB meetings were conducted as planned, in which the study's progress, execution, results, and
 293 adverse event reports were reviewed by the committee members. At each meeting, the decision was
 294 made to proceed with the study accrual. A total of 377 adverse events were identified in the study. All
 295 patients had at least one adverse event, with an average of 4.7 events per patient. The majority of adverse

296 events (61%) were mild in severity and did not cause harm to patients. Furthermore, 78% of the reported
 297 adverse events were judged by a blinded assessor to be not related to the study, 21% “possibly related”,
 298 and 1% “definitely related” to the study treatment. The most common adverse events were hypertension
 299 (65%), followed by increase in alanine aminotransferase, hypoalbuminemia, and sinus bradycardia (43.8%
 300 for the three events). Only increased aspartate aminotransferase level was found to be significantly higher
 301 in the anakinra group compared to the SOC group (35% vs. 15%), respectively, (p=0.039). Four serious
 302 adverse events were reported in the study, two in the anakinra group and two in the SOC group. To
 303 elaborate, one patient in the SOC died 23 days after randomization due to worsening of his pre-existing
 304 medical condition, while the second patient had a prolonged hospital stay due to diarrhea, in which both
 305 were judged to be unrelated to study interventions. In the anakinra group, both patients were re-admitted
 306 to the hospital for 3-6 days after two weeks of randomization due to suspected respiratory tract
 307 infections, which were judged to be possibly related to the study interventions. Table 3 summarizes the
 308 common adverse events reported in the study.

Table 3: Reported Adverse Events for Study Groups

Adverse events, n (%)	Overall (n=80)	Anakinra (n=40)	Standard of care (n=40)	P-value
Incidence of at least one AE	80 (100)	40 (50)	40 (50)	NA
Average number of AE per patient	4.7	4.7	4.72	0.034
Serious AE	4 (5)	2 (2.5)	2 (2.5)	NA
Number of Adverse events	377/377 (100)	201/377 (53)	176/377 (47)	NA
Severe AE (grade 4-5)	1/377 (0)	0/377 (0)	1/377 (0)	NA
Mild-Moderate AE (grade 1-3)	376/ 377 (100)	201/377 (53)	175/377 (46)	0.034
Relatedness to study intervention				
Not related	294/377 (78)	154/377 (41)	140/377 (37)	0.863
Possibility related	79/377 (21)	44/377 (12)	35/377 (9)	0.534
Probably related	2/377 (1)	1/377 (0)	1/377 (0)	NA
Definitely related	2/377 (1)	2/377 (1)	0/377 (0)	NA
Common AE (incidence > 5%)				
Hypertension	52 (65.0)	27 (67.5)	25 (62.5)	0.639
Alanine aminotransferase increased	35 (43.8)	19 (47.5)	16 (40.0)	0.499
Hypoalbuminemia	35 (43.8)	18 (45.0)	17 (42.5)	0.822
Sinus Bradycardia	35 (43.8)	16 (40.0)	19 (47.5)	0.499
Hypotension	32 (40.0)	19 (47.5)	13 (32.5)	0.171
Anemia	21 (26.3)	8 (20.0)	13 (32.5)	0.204
Aspartate aminotransferase increased	20 (25.0)	14 (35.0)	6 (15.0)	0.039
Hyponatremia	20 (25.0)	11 (27.5)	9 (22.5)	0.606

Hyperglycemia	17 (21.3)	9 (22.5)	8 (20.0)	1
Lymphocyte count decreased	15 (18.8)	8 (20.0)	7 (17.5)	0.775
ECG QT corrected interval prolonged	9 (11.3)	5 (12.5)	4 (10.0)	1
Alkaline phosphatase increased	8 (10.0)	5 (12.5)	3 (7.5)	0.712
Diarrhea	8 (10.0)	3 (7.5)	5 (12.5)	0.712
Hyperkalemia	7 (8.8)	5 (12.5)	2 (5.0)	0.432
Hypokalemia	7 (8.8)	3 (7.5)	4 (10.0)	1
Sinus tachycardia	6 (7.5)	4 (10.0)	2 (5.0)	0.675
Lymphocyte count increased	4 (5.2)	2 (5.0)	2 (5.0)	1.000
Creatinine increased	4 (5.2)	2 (5.0)	2 (5.0)	1.000

309

310 **Discussion:**

311 This open-label randomized multicenter clinical trial conducted in Qatar between October 2020 and April
312 2021, found that anakinra administered SC was not more efficacious than the SOC therapy in patients
313 with COVID-19 pneumonia in terms of achieving higher rates of treatment success; defined as a WHO
314 clinical progression score of 3 or less. The use of anakinra was also not associated with a significant change
315 in the WHO clinical progression score or reducing viral burden at 14 days when compared to usual care.
316 The length of stay and the time to ICU admission for non-ICU patients did not differ between the two
317 groups. The overall mortality rate was low in this trial (1.25%) as only one death was reported in the SOC
318 group.

319 The main findings in our trial are consistent with that of the randomized clinical trial by the CORIMUNO
320 collaborative group from France ^[15], which is the only published RCT investigating the use of anakinra to
321 this date. The CORIMUNO-ANA-1 trial was an open-label, multicenter, randomized controlled trial of
322 anakinra administered intravenously (IV) for 5 days compared to usual care to assess its survival benefits
323 and the need for mechanical ventilation at day 4. Similar to our population, the CORIMUNO trial included
324 patients with a WHO clinical progression score of ≥ 5 . The two primary outcomes were not significant,
325 and the need for mechanical or non-invasive ventilation at day 14 was also not different in both groups.
326 Overall mortality at days 28 and 90 did not differ between the groups, and as a result the trial was
327 prematurely stopped for futility.

328 Anakinra is FDA approved for use in rheumatoid arthritis, neonatal-onset multisystem inflammatory
329 disease, and deficiency of IL-1 receptor antagonist. It has also been utilized in various other clinical
330 situations, most notably its off-label use in the treatment of hemophagocytic lympho-histiocytosis and
331 cytokine storms ^[16,17]. The hyperinflammation seen in patients with COVID-19 pneumonia is associated

332 with severe disease presentation and is often identifiable by elevation of common inflammatory markers
333 such CRP, IL-6, and procalcitonin, as well as other cytokines ^[18]. In addition, earlier studies suggested a
334 significant role of raised cytokines, including IL-1, in severe COVID-19 pneumonia, which hypnotized a
335 potential role of IL-1 inhibitors in patients with COVID-19 pneumonia ^[6,17].

336 Several case series and observational studies suggested the potential clinical improvement and mortality
337 benefit of anakinra use in COVID-19 pneumonia ^[19-21]. A recent meta-analysis of 15 observational and
338 interventional studies with a total of 3530 patients suggested that there is an overall mortality benefit
339 with the use of anakinra when compared to usual care ^[22]. Evidence also suggested that anakinra can
340 prevent the progression to severe disease and reduce the need for mechanical ventilation. However,
341 these studies were limited by the lack of randomization and the potential for selection and confounding
342 bias, as well as the significant heterogeneity observed in the meta-analysis outcomes.

343 Unfortunately, the mortality benefit observed in the previous observational studies was not observed in
344 our trial or the CORIMUNO-ANA-1 trial ^[15]. Despite including patients with severe COVID-19 pneumonia,
345 this trial reported only one patient death (1.25%) in the SOC group. On the other hand, the CORIMUNO-
346 ANA-1 trial reported an overall mortality rate of 28 % in each group. The advanced SOC may partly explain
347 the low mortality rate in this trial compared to the CORIMUNO-ANA-1 trial. To explain, in the three sites,
348 SOC for all patients included administration of dexamethasone and remdesivir as per the national
349 treatment guidelines. However, none of the CORIMUNO-ANA-1 trial patients received antivirals like
350 remdesivir or favipravir, and dexamethasone was not established as part of routine care for moderate to
351 severe pneumonia by then. Dexamethasone in the RECOVERY trial showed mortality benefit and,
352 eventually, became standard of care globally for treating severe COVID-19^[23]. The Infectious Disease
353 Society of America treatment guidelines recommend using remdesivir in patients requiring supplemental
354 oxygen and in patients with moderate to severe COVID-19 pneumonia, given its proven clinical benefits
355 in this population ^[24].

356 There is an increased interest to prevent severe respiratory failure and the need for intubation and
357 mechanical ventilation in patients presenting with COVID-19 pneumonia. Small case series from the
358 United States initially showed that IV administration of anakinra prevented the development of severe
359 acute hypoxic respiratory failure^[19]. Another meta-analysis of seven studies (including the CORIMUNO
360 ANA-1 trial), with a total of 740 patients receiving anakinra, showed that anakinra reduced the need for
361 invasive mechanical ventilation^[22]. The considerable heterogeneity in these studies as well as the
362 predominantly retrospective and observational nature of those studies, warranted the confirmation of

363 these findings in a randomized clinical trial. However, no significant benefit was observed by either this
364 trial or the CORIMUNO- ANA-1 trial with regards to the rates of invasive mechanical ventilation.

365 The preferred core outcomes for clinical studies as defined by the WHO working group^[13] were used in
366 this trial. Cycling Threshold (CT) is used as a marker of viral load, as it is inversely related to the viral load
367 and provides an indirect method of quantifying the copy number of viral RNA^[25]. Anakinra did not affect
368 the viral burden when compared to the SOC group in this study. Furthermore, the WHO clinical
369 progression scale is a 10-point ordinal scale from 0 (no disease) to 10 (dead). It was chosen as an objective
370 outcome measure to reduce the variability and heterogeneity seen in the previous studies and allow
371 comparisons with future studies. No significant changes were reported in the baseline of the WHO clinical
372 progression score or the seven-days score between the two groups.

373 Overall, a higher prevalence of adverse events was reported in this trial as compared to other studies,
374 with every patient experiencing at least one adverse event. The most commonly reported adverse events
375 were hypertension, raised liver transaminases, and hypoalbuminemia. Only AST elevation was
376 significantly higher in the anakinra group. Although AST elevation is one of the possible adverse effects of
377 anakinra, the possibility that the reported increase in this trial might be due to the multiple concomitant
378 medications taken by the patients cannot be denied. Overall, the incidence of severe adverse events did
379 not exceed 5%. The high prevalence of adverse events in our trial may partially be attributed to the robust
380 data collection and the additional concomitant use of antivirals as part of SOC therapy compared to SOC
381 in other studies. Convalescent plasma has also been part of Qatar's national guidelines, and patients
382 received it as per protocol. The decision was made by the treating physician in line with the criteria set
383 for use as per the national CDC guidelines (refer to supplementary materials).

384 There is increased awareness of the concept of the possible narrow therapeutic window to treat cytokine
385 storms with cytokine inhibitors as well as the right time to initiate IL-1 inhibitors^[26]. There is a need to
386 define if certain inflammatory markers or other biomarkers can guide the right timing for the use of
387 anakinra. Soluble urokinase plasminogen activator receptor (SuPAR), a molecular measurable marker, is
388 associated with increased risk of severe respiratory failure and has also been found to be elevated in
389 patients with COVID-19^[27,28]. An open-label non-randomized interventional trial (SAVE) was done to
390 assess the use of anakinra to prevent progression to severe COVID-19 disease ^[29]. The trial included 130
391 patients in the anakinra group and 130 propensity-matched SOC comparator cohort. Patients who had a
392 level higher than 6 microg/l were deemed at risk of developing severe respiratory failure and, thus, were
393 treated with anakinra. Anakinra successfully prevented the need for mechanical ventilation and

394 demonstrated mortality benefits. SAVE trial, although inadequate randomization, provided additional
395 insights that patients with biomarker-guided therapy may be better candidates to receive the specific
396 interleukin inhibitors. This is being investigated by the ongoing placebo-controlled randomized (SAVE-
397 MORE) phase III trial assessing the effects of biomarker-guided use of anakinra in patients.
398 (www.clinicaltrials.gov, NCT04680949)^[27]. Similarly, another non-randomized study, where ferritin was
399 used as a biomarker to guide therapy, showed significantly improved clinical outcomes, including reduced
400 mortality rates and progression to severe COVID-19 by early administration of therapy either with
401 anakinra alone or in combination with steroids^[30].

402 The route of administration of anakinra used in our trial was subcutaneous, while it was intravenously
403 administered in the CORIMUNO-ANA-1 trial. Both did not show any significant benefits in their defined
404 outcomes. Whether higher doses or extended duration of anakinra could have benefited the COVID-19
405 patients is unknown and may warrant further investigation.

406 This trial has some limitations. First, a placebo was not used in this trial due to the nature of the pandemic
407 and the urgency to answer the clinical question. In addition, there is a potential for bias due to the open-
408 label nature of the trial. However, this was minimized by choosing objective outcomes and blinding the
409 outcome assessors. Finally, the overall sample size was small, especially for patients with severe disease
410 or mechanical ventilation; hence, subgroups analysis in this population was not feasible.

411 On the other hand, this trial has several strengths. This trial is one of the few randomized trials conducted
412 on COVID-19 patients after establishing a better SOC (steroids, remdesivir). Moreover, it was a multicenter
413 trial involving multiple ethnic groups, contributing to the study results' higher generalizability. The WHO's
414 recommended outcomes for clinical studies were used; those included the WHO clinical progression
415 score, viral burden as measured by the cyclic threshold, and the overall mortality, which facilitate the
416 comparison of this trial's results to other similar trials. Furthermore, this trial was conducted in Qatar
417 where well-established national guidelines for COVID-19 treatment exist. Finally, no significant loss of
418 follow-up rate was reported in this study.

419 **Conclusion:**

420 In patients with severe COVID-19 pneumonia requiring oxygen therapy, the addition of anakinra to the
421 SOC treatment was not associated with significant improvement in the WHO clinical progression scale.
422 Therefore, there is a need for determining the subgroups of COVID-19 patients who will benefit the most
423 by the timely administration of anakinra.

424 **Author Contributions**

425 Conceptualization and Methodology: *Eman Elmekaty*. Data Validation: *Mohamed Aboukamar, Waqar*
426 *Munir, Rim Alibrahim, Eman Elmekaty*. Formal analysis and Visualization: *Mohamed Izham*. Investigations:
427 *Waqar Munir, Ahmed Al Bishawi, Arun Nair, Aya Maklad, Rawan Abouelhassan, Fatima Iqbal, Mohammed*
428 *AbuKhattab, Rim Alibrahim, Mohamed Aboukamar, Alaaeldin Abdelmajid*. Resources: *Hussam Al Soub,*
429 *Mohammed AbuKhattab, Muna Al Maslamani*. Data curation: *Aya Maklad, Rawan Abouelhassan, Eman*
430 *Elmekaty*. Writing – original draft: *Ahmed Al Bishawi, Arun Nair, Mohamed Izham, Fatima Iqbal*. Writing
431 – review & editing: *Aya Maklad, Rawan Abouelhassan, Mohamed AbuKhattab, Eman Elmekaty, Hussam*
432 *Al Soub, Alaaeldin Abdelmajid*. Supervision: *Hussam Al Soub, Muna Al Maslamani*.

433 **Data sharing**

434 Deidentified participants data (in spreadsheet form, with included data definitions) will be made available
435 for sharing after publication on reasonable requests made to the corresponding author. Data can be
436 shared through secure online platforms after being approved by the principal investigator.

437 **Declaration of interests**

438 All authors declare that they have no conflict of interest.

439 **Acknowledgments:**

440 We would like to thank all physician assistants working in Hamad Medical Corporation COVID-19
441 facilities for their outstanding support and dedication.

442 **References**

- 443 1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2
444 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J*
445 *Antimicrob Agents*. 2020 Feb 17:105924. doi: 10.1016/j.ijantimicag.2020.105924. [Epub ahead of
446 print]
- 447 2. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization, 2020.
448 <https://Covid19.who.int/>. [Accessed 29 March 2020.]
- 449 3. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China.
450 *MedRxiv* 2020: 2020.02.06.20020974.
- 451 4. WHO Director-General's opening remarks at the media briefing on COVID-19 - 3 March 2020 -
452 World Health Organization, March 3, 2020

- 453 5. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate
454 coronavirus disease 2019. *J Clin Invest* 2020;130:2620-9. doi:10.1172/JCI137244
- 455 6. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and
456 immunosuppression. *Lancet* 2020; 395: 1033–34.
- 457 7. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in
458 COVID-19 induced pneumonia and macrophage activation syndrome-like disease. *Autoimmun*
459 *Rev* 2020; published online April 3. DOI:10.1016/j.autrev.2020.102537.
- 460 8. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1
461 receptor blockade is associated with reduced mortality in sepsis patients with features of
462 macrophage activation syndrome: reanalysis of a prior phase III trial. *Crit Care Med*. 2016;44:275–
463 81.
- 464 9. Opal SM, Fisher Jr CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1
465 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-
466 controlled, multicenter trial. *Crit Care Med*. 1997;25:1115–24.
- 467 10. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. *Lancet*
468 *Rheumatol*. 2020;9913(20):1-8. doi:10.1016/s2665-9913(20)30164-8
- 469 11. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in
470 patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a
471 retrospective cohort study. *Lancet Rheumatol*. 2020;2(6):e325-e331. doi:10.1016/S2665-
472 9913(20)30127-2
- 473 12. Langer-Gould A, Smith JB, Gonzales EG, et al. Early identification of COVID-19 cytokine storm and
474 treatment with anakinra or tocilizumab. *Int J Infect Dis*. 2020;99:291-297.
475 doi:10.1016/j.ijid.2020.07.08
- 476 13. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome
477 measure set for COVID-19 clinical research. *The Lancet Infectious Diseases*. 2020;20(8):e192-e7.
- 478 14. National Cancer Institute. Common Terminology Criteria for Adverse Events - Version 5.0.
479 2017. Available from: [https://ctep.cancer.gov/protocoldevelopment/electronic_applications](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)
480 [/docs/ctcae_v5_quick_reference_5x7.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)
- 481 15. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate
482 pneumonia (CORIMUNO-ANA-1): a randomized controlled trial. *Lancet Respir Med*. 2021
483 Mar;9(3):295–304.

- 484 16. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra,
485 an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic
486 lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in
487 critically ill children*. *Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit*
488 *Care Soc.* 2014 Jun;15(5):401–8.
- 489 17. Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of
490 intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation
491 syndrome. *Lancet Rheumatol.* 2020 Jun;2(6):e358–67.
- 492 18. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the
493 severity of COVID-19: A meta-analysis. *Int J Infect Dis.* 2020 Jul;96:467–74.
- 494 19. Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to Prevent
495 Mechanical Ventilation in Severe COVID-19: A Case Series. *Arthritis Rheumatol Hoboken Nj.* 2020
496 Jun 30;10.1002/art.41422.
- 497 20. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory
498 cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. *Ann Rheum Dis.*
499 2020 Oct;79(10):1381–2.
- 500 21. Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al.
501 Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic
502 Lymphohistiocytosis. *Cell Host Microbe.* 2020 Jul 8;28(1):117-123.e1.
- 503 22. The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A
504 Systematic Review and Meta-Analysis [Internet]. [cited 2021 Aug 14]. Available from:
505 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258297/>
- 506 23. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 —
507 Preliminary Report. *N Engl J Med.* 2020 Jul 17;NEJMoa2021436.
- 508 24. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, et al. Infectious Diseases
509 Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clin*
510 *Infect Dis Off Publ Infect Dis Soc Am.* 2020 Apr 27;ciaa478.
- 511 25. Rao SN, Manissero D, Steele VR, Pareja J. A Narrative Systematic Review of the Clinical Utility of
512 Cycle Threshold Values in the Context of COVID-19. *Infect Dis Ther.* 2020 Sep;9(3):573–86.
- 513 26. Cavalli G, Dagna L. The right place for IL-1 inhibition in COVID-19. *Lancet Respir Med.* 2021
514 Mar;9(3):223–4.

- 515 27. Hellenic Institute for the Study of Sepsis. suPAR-Guided Anakinra Treatment for Validation of the
516 Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-
517 blind, Randomized, Phase III Confirmatory Trial [Internet]. clinicaltrials.gov; 2021 Apr [cited 2021
518 Aug 12]. Report No.: NCT04680949. Available from:
519 <https://clinicaltrials.gov/ct2/show/NCT04680949>
- 520 28. Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble
521 urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory
522 failure in patients with COVID-19 pneumonia. *Crit Care*. 2020 Apr 30;24:187.
- 523 29. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open
524 label trial of anakinra to prevent respiratory failure in COVID-19. *eLife*. 10:e66125.
- 525 30. Dalekos GN, Stefos A, Georgiadou S, Lygoura V, Michail A, Ntaios G, et al. Lessons from
526 pathophysiology: Use of individualized combination treatments with immune interventional
527 agents to tackle severe respiratory failure in patients with COVID-19. *Eur J Intern Med*. 2021
528 Jun;88:52–62.
- 529